Desh Rakshak Aushdhalaya Ltd
₹ 26.9
0.00%
14 Aug
- close price
About
Incorporated in 1901, Desh Rakshak Aushdhalaya Ltd manufactures Ayurvedic and Herbal Products[1]
Key Points
- Market Cap ₹ 15.3 Cr.
- Current Price ₹ 26.9
- High / Low ₹ 81.0 / 22.4
- Stock P/E 27.9
- Book Value ₹ 23.3
- Dividend Yield 0.00 %
- ROCE 6.53 %
- ROE 4.82 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.15 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 1.59% over past five years.
- Company has a low return on equity of 4.80% over last 3 years.
- Company has high debtors of 472 days.
- Promoter holding has decreased over last 3 years: -14.2%
- Working capital days have increased from 203 days to 326 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.44 | 4.98 | 5.05 | 5.05 | 5.51 | 5.06 | 6.56 | 6.14 | 6.13 | 5.95 | 6.18 | 7.10 | 6.63 | |
| 3.79 | 4.26 | 4.39 | 4.34 | 4.73 | 4.27 | 5.61 | 4.94 | 4.74 | 4.66 | 4.92 | 5.72 | 5.23 | |
| Operating Profit | 0.65 | 0.72 | 0.66 | 0.71 | 0.78 | 0.79 | 0.95 | 1.20 | 1.39 | 1.29 | 1.26 | 1.38 | 1.40 |
| OPM % | 14.64% | 14.46% | 13.07% | 14.06% | 14.16% | 15.61% | 14.48% | 19.54% | 22.68% | 21.68% | 20.39% | 19.44% | 21.12% |
| 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | -0.05 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Interest | 0.12 | 0.11 | 0.11 | 0.13 | 0.13 | 0.16 | 0.16 | 0.24 | 0.42 | 0.37 | 0.31 | 0.28 | 0.29 |
| Depreciation | 0.45 | 0.24 | 0.22 | 0.24 | 0.25 | 0.27 | 0.26 | 0.40 | 0.44 | 0.44 | 0.42 | 0.44 | 0.44 |
| Profit before tax | 0.08 | 0.38 | 0.34 | 0.35 | 0.41 | 0.37 | 0.55 | 0.57 | 0.48 | 0.50 | 0.56 | 0.67 | 0.68 |
| Tax % | 75.00% | 23.68% | 17.65% | 20.00% | 19.51% | 18.92% | 23.64% | 15.79% | 14.58% | 16.00% | 16.07% | 16.42% | |
| 0.02 | 0.29 | 0.28 | 0.28 | 0.34 | 0.30 | 0.42 | 0.48 | 0.41 | 0.43 | 0.48 | 0.56 | 0.55 | |
| EPS in Rs | 0.05 | 0.65 | 0.63 | 0.63 | 0.77 | 0.68 | 0.95 | 1.08 | 0.92 | 0.97 | 1.08 | 0.98 | 0.97 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 7% |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | % |
| 3 Years: | 65% |
| 1 Year: | -67% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 5.92 |
| Reserves | 2.15 | 2.46 | 2.74 | 3.02 | 3.45 | 3.72 | 4.14 | 4.62 | 4.47 | 4.82 | 5.29 | 7.37 |
| 1.06 | 1.47 | 0.69 | 0.96 | 1.23 | 2.03 | 2.90 | 4.31 | 4.10 | 2.78 | 3.04 | 2.80 | |
| 1.71 | 1.49 | 2.07 | 2.16 | 2.01 | 1.91 | 2.87 | 2.53 | 2.51 | 4.06 | 4.99 | 4.80 | |
| Total Liabilities | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 17.98 | 20.89 |
| 3.69 | 3.75 | 3.87 | 3.93 | 4.39 | 5.38 | 6.49 | 7.82 | 8.07 | 7.68 | 7.84 | 8.20 | |
| CWIP | 1.35 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 1.87 | 1.39 |
| Investments | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| 4.42 | 3.84 | 3.80 | 4.38 | 4.47 | 4.45 | 5.66 | 5.88 | 5.25 | 6.22 | 8.22 | 11.25 | |
| Total Assets | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 17.98 | 20.89 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.27 | 1.27 | 0.23 | -0.15 | -0.55 | 0.59 | 0.84 | 0.23 | 0.45 | 1.52 | -0.30 | -1.31 | |
| -0.45 | -0.66 | -0.76 | 0.04 | 0.42 | -1.27 | -1.26 | -1.95 | -0.78 | -0.09 | -0.02 | -1.64 | |
| 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.74 | 0.80 | 1.35 | 0.15 | -1.34 | 0.25 | 3.02 | |
| Net Cash Flow | -0.18 | 0.61 | -0.53 | -0.04 | -0.12 | 0.06 | 0.37 | -0.36 | -0.18 | 0.09 | -0.07 | 0.08 |
| Free Cash Flow | -0.24 | 0.20 | -0.11 | 0.25 | 0.07 | -0.66 | -0.54 | -1.51 | -0.20 | 1.47 | -0.37 | -2.81 |
| CFO/OP | 42% | 188% | 44% | -11% | -60% | 84% | 102% | 27% | 37% | 124% | -17% | -84% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 127.42 | 125.33 | 146.72 | 179.25 | 196.08 | 221.45 | 214.77 | 236.00 | 216.74 | 314.70 | 434.10 | 471.93 |
| Inventory Days | 215.33 | 160.82 | 191.55 | 193.41 | 120.33 | 123.23 | 72.16 | 117.52 | 107.51 | 46.01 | 29.26 | 30.62 |
| Days Payable | 247.41 | 195.79 | 242.83 | 257.39 | 219.27 | 249.57 | 270.87 | 315.23 | 301.29 | 584.31 | 726.92 | 494.83 |
| Cash Conversion Cycle | 95.35 | 90.37 | 95.44 | 115.26 | 97.14 | 95.11 | 16.06 | 38.29 | 22.96 | -223.60 | -263.56 | 7.72 |
| Working Capital Days | 180.03 | 94.55 | 117.81 | 148.89 | 153.02 | 162.30 | 117.40 | 164.07 | 149.45 | 108.58 | 174.82 | 325.93 |
| ROCE % | 2.56% | 5.95% | 5.40% | 5.74% | 6.01% | 5.37% | 6.42% | 6.41% | 7.08% | 6.83% | 6.89% | 6.53% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Export Sales as % of Total Sales % |
|
||||||||
| Installed Capacity - Awaleha Tonnes |
|||||||||
| Installed Capacity - Capsules lacs Nos. |
|||||||||
| Installed Capacity - Kwath Tonnes |
|||||||||
| Installed Capacity - Liquids (Syrups) lacs bottles |
|||||||||
| Installed Capacity - Pills lacs Nos. |
|||||||||
| Installed Capacity - Tablets lacs Nos. |
|||||||||
| Number of Permanent Employees (incl. KMP & Directors) employees |
|||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026 pursuant to Regulation 30 and Regulation 47 of the SEBI (LODR) ....
-
Statement Of No Deviation(S) Or Variation(S) In The Use Of Proceeds And Utilization Of Funds Relating To Allotment Of Equity Shares On Preferential Basis Under Regulation 32 Of The SEBI (LODR) Reg, 2015
- Reports no deviation in use of Rs. 2.77 crore preferential issue proceeds for quarter ended June 30, 2026.
- Submission Of Quarterly And Year To Date Unaudited Financial Results For The Quarter Ended 30Th June, 2026 As Per Regulation 33 Of The SEBI (LODR), Regulations, 2015
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 13Th Day Of August, 2026 Pursuant To Para A Of Part A Of Schedule III And Regulation 30 Of The SEBI (LODR) Reg, 2015
- Board approved Q1 FY27 results for quarter ended 30 June 2026 with unmodified auditor review.
-
Board Meeting Intimation for Pre Intimation Of The Board Meeting As Per Regulation 29 Of The SEBI (LODR) Reg, 2015 And Closure Of Trading Window
- Board meeting on 13 August 2026 to approve Q1 results, review RTA agreement, and keep trading window closed.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
-
Annual Report 2010
from bse
-
Annual Report 2009
from bse
Business Overview:[1][2]
DRAL is the flagship company of Bhagwant Group and one of the oldest manufacturers of Pure Ayurvedic and Herbal Products. It has a wide range of ethical medicines that are derived from herbs and form part of this holistic healthcare system. The medicines are categorized into Proprietary & Classical Medicines. The company is currently manufacturing around 450 products which are GMP certified.